Universities & institutes at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

92 universities & institutes are at CTAD 2026 — 225 presentations on the program. Most represented: Washington University in St. Louis (15 on the program), USC Alzheimer's Therapeutic Research Institute (12 on the program), Stanford University (9 on the program). 45 of them have their own page in this guide. As of Oct 8, 2026.

All 315 organizations at CTAD 2026 →

Showing 1–4 of 92 organizations

Organization	CTAD 2026 Attendance
Washington University in St. Louis St. Louis, Missouri
washu.edu Universities & institutes Leads the DIAN network and DIAN-TU trials in inherited Alzheimer's disease, and runs the Knight Alzheimer Disease Research Center.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Senolytic Therapy in Early Alzheimer’s Disease: A Randomized Phase II Trial Suggests Effects on CSF Tau Biomarkers (P036) Other mechanisms and targets · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Spatiotemporal Emergence and Longitudinal Progression of Tau-PET Pathology in Autosomal Dominant Alzheimer Disease: Implications for Prevention Trial Design (P085) PET and MRI imaging · Prevention and early disease Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue GPND-AI Treatment: A Trajectory Monitor for Treatment Responses (P123) Digital assessment and AI Session Mon Nov 16 4:50pm–5:30pm Visualizing the Brainshuttle™: Pioneering neuroimaging and mechanistic insights of amyloid clearance with trontinemab Anti-amyloid and anti-tau therapies · PET and MRI imaging Talk Mon Nov 16 5:30pm Agentic Artificial Intelligence in Alzheimer’s Disease Clinical Trials: From Data-Driven Discovery to Adaptive Design Optimization and Statistical Validation Digital assessment and AI · Trial design and endpoints Talk Tue Nov 17 3:30pm Plasma Tau Isomerization at Residue D54 as a Scalable Biomarker of Brain Tau Aggregation in Early-Onset Alzheimer’s Disease Blood and CSF biomarkers Poster Wed Nov 18 7:15am–5:30pm Quantum Capacitance Electrochemical Biosensor for the Rapid and Ultrasensitive Detection of p-tau217 and MTBR-tau243 (P257) Blood and CSF biomarkers Talk Wed Nov 18 9:15am Estimating 15-Year absolute risk of cognitive impairment in cognitively unimpaired older adults with Alzheimer disease biomarkers based on amyloid PET or plasma %p-tau217 Prevention and early disease · Blood and CSF biomarkers Talk Wed Nov 18 2:25pm Calibrated age of onset for amyloid positivity from plasma %p-tau217 leads to better design and improved representation of Black Americans in Alzheimer disease clinical trials: Simpson’s paradox Blood and CSF biomarkers · Trial design and endpoints Talk Wed Nov 18 4:45pm Combining Plasma p-Tau217 with Proteomic Signatures Enables Graded Risk Stratification for Alzheimer’s Disease Progression Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Prognostic versus propensity-score covariates for trial efficiency across the Alzheimer’s disease spectrum: an evaluation in dominantly-inherited and preclinical AD (P377) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Symmetric Centipolar Normalized Score (SCeNS): a standardization framework for fluid marker cross-comparability in Alzheimer’s disease (P383) Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Listening Before Recruiting: Community Listening Sessions to Improve Alzheimer’s Research Engagement (P387) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Smart Triage for Amyloid-Targeting Therapies (STATT) (P499) Real-world data and access · Anti-amyloid and anti-tau therapies Talk Thu Nov 19 1:05pm Dynamic changes in plasma biomarkers in patients treated with lecanemab: a longitudinal cohort study Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers
USC Alzheimer's Therapeutic Research Institute San Diego, California
atri.usc.edu Universities & institutes USC academic center that designs, coordinates and analyzes Alzheimer's trials such as A4 and AHEAD; part of the Alzheimer's Clinical Trials Consortium.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Site Engagement Within a Centralized Recruitment, Engagement, and Retention Framework: The Alzheimer’s Clinical Trials Consortium Experience (P179) Trial design and endpoints Session Mon Nov 16 3:15pm–3:25pm Welcome Ceremony and CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research with Brigham and Women's Hospital, Toulouse University Hospital, Imperial College London +3 more Session Tue Nov 17 11:05am–11:45am Remote Digital Biomarkers in Alzheimer’s Disease Clinical Trials: From Scalable Prescreening to Sensitive AI-Enabled Assessment Digital assessment and AI · Trial design and endpoints · with University of California, San Francisco Talk Wed Nov 18 8:30am Brain-Derived pTau217 Outperforms 328 Plasma Proteins for Association with Amyloid and Tau Accumulation and Cognitive Progression in the A4 and LEARN Studies Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Disaggregating Asian Populations in a Global Preclinical Alzheimer’s Disease Trial: Recruitment, Screening and Randomization in the AHEAD 3-45 Study (P363) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Plasma p-tau217 In Early Alzheimer’s Disease Trial Screening: Insights from START (P365) Blood and CSF biomarkers · Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Leveraging Anti-Amyloid Clinical Trial Screening to Establish a Longitudinal Primary Prevention Cohort: APEX Recruitment Strategy and Baseline Findings (P375) Prevention and early disease · Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Responsible Data Sharing at Scale: Building Tiered Open Science Infrastructure for ADRD Clinical Trials (P391) Real-world data and access Poster Thu Nov 19 7:15am–5:00pm Promoting dementia research participation in high-risk communities – co-creating a Research Ambassador Program. (P445) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Baseline Completion and Retention with a New Cognitive Assessment in an Online Alzheimer’s Disease Trial Registry: Results from the APT Webstudy (P502) Digital assessment and AI · Trial design and endpoints Talk Thu Nov 19 8:30am–9:10am Part of Lessons from The Life’s end Benefits of cannaBidiol and tetrahydrocannabinol (LiBBY) Study: Efficacy, Implementation, and Future Therapeutic Development in Advanced Dementia Advancing Trials in Dementia: Lessons from LiBBY and a Future Research Agenda for the Alzheimer’s Clinical Trial Consortium (ACTC) Trial design and endpoints · Neuropsychiatric symptoms Talk Thu Nov 19 10:40am–11:05am Beyond Amyloid and Tau: Roles of Proteomics in Clinical Trials Blood and CSF biomarkers · with Emory University Talk Thu Nov 19 2:50pm Biomarker Associations and Outcome Performance in Preclinical Alzheimer Disease Trials Trial design and endpoints · Prevention and early disease Talk Thu Nov 19 3:20pm Cross-platform performance of plasma p-tau217 assays for predicting amyloid PET positivity across cohorts Blood and CSF biomarkers Talk Thu Nov 19 3:35pm Plasma %p-tau217 and Aβ42/Aβ40 provide complementary information about amyloid PET below 20 Centiloids: Baseline findings from the Alzheimer’s Plasma Extension Study Blood and CSF biomarkers
Stanford University Stanford, California
stanford.edu Universities & institutes Runs the Stanford Alzheimer's Disease Research Center, studying biomarkers, imaging and cognitive ageing.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Cross-sectional and longitudinal factor analysis of everyday activity and cognition in cognitively unimpaired older adults: the Stanford Aging and Memory Study 7-Year Follow-Up (P136) Prevention and early disease · Trial design and endpoints Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue The population-level impact of herpes zoster vaccination on dementia-related and all-cause mortality: Evidence from country-wide death certificate data for England (P151) Prevention and early disease Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Sex-Divergent Plasma Proteomic Alterations and cognitive profiling in Bone-Related Pathways Across the Alzheimer’s Disease (P165) Blood and CSF biomarkers · Other mechanisms and targets Talk Mon Nov 16 4:05pm POLARIS-AD: A Global Phase 3 Trial of AR1001 in Early Alzheimer’s Disease: Efficacy Outcomes at 52 Weeks and Safety Through the Extension Phase Other mechanisms and targets Talk Tue Nov 17 3:45pm Preventing Dementia with Shingles Vaccination? Evidence from Quasi-Randomized Vaccine Rollouts Prevention and early disease Talk Wed Nov 18 1:55pm LM11A-31 reduces CSF levels of eMTBR-tau243: a retrospective analysis of a phase 2a safety and exploratory biomarker trial in mild-moderate Alzheimer’s disease Other mechanisms and targets · Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Cross-omic and clinicopathological profiling of cellular senescence signatures in Alzheimer’s disease (P398) Other mechanisms and targets Poster Thu Nov 19 7:15am–5:00pm High-Frequency Monitoring of Cognitive and Biomarker Changes in Healthy Aging Over One Year (P416) Digital assessment and AI · Blood and CSF biomarkers Poster Thu Nov 19 7:15am–5:00pm Effects of regional tau accumulation on visual discrimination behaviors in clinically unimpaired older adults (P426) PET and MRI imaging · Trial design and endpoints · Rising Stars Showcase Talk Thu Nov 19 2:35pm Amyloid and Tau PET Biological Staging Across Ethnoracial Groups in a Multi-Cohort Alzheimer’s Disease Study PET and MRI imaging
University of California, Irvine Irvine, California
uci.edu Universities & institutes Its Institute for Memory Impairments and Neurological Disorders (UCI MIND) runs Alzheimer's research, including Down syndrome studies.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Alzheimer disease in Down syndrome: A decade of biomarker discovery and a pathway to clinical trials. (P084) PET and MRI imaging · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Undetected Diabetes, Glycemic Status and Cognitive Outcomes in Hispanic/Latino Adults in Southern California: Baseline Findings from SERVE OC (P157) Prevention and early disease Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Non-Melanoma Skin Cancer, but Not Systemic Cancer History, Is Associated with Faster Plasma P-tau217 Accumulation and Cognitive Decline in Cognitively Unimpaired Older Adults: A Longitudinal ADNI Analysis (P161) Prevention and early disease · Blood and CSF biomarkers Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Treatment of age-related upstream bioenergetic and redox impairment promotes clearance of Aβ and tau aggregates, lowers oxidative nitration and promotes synapse formation in isolated neurons from AD mouse models (P184) Other mechanisms and targets Poster Thu Nov 19 7:15am–5:00pm Assessing Efficiency in Adaptive ADRD Trial Frameworks: A Systematic Comparison of Group Sequential and Promising Zone Designs (P364) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Digital Cognitive Signatures of Biomarker-Defined Preclinical Alzheimer’s Disease (P433) Digital assessment and AI · Prevention and early disease · Rising Stars Showcase Poster Thu Nov 19 7:15am–5:00pm A Digital Memory Task Enables Efficient Identification of Cognitive Impairment in Alzheimer’s Disease Trials (P436) Digital assessment and AI Poster Thu Nov 19 7:15am–5:00pm Evaluating Research Attitudes and Willingness to Participate in Alzheimer’s Disease and Related Dementias Clinical Trials Across Disaggregated AANHPI Subgroups: Data from the CARE Registry (P494) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Study partner availability and willingness to be contacted about clinical trials in a local recruitment registry (P496) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm The Effect of Messaging on Research Enrollment (P500) Trial design and endpoints

Instantly find 20 buyers from universities & institutes

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction

Instantly find 20 buyers from universities & institutes

Browse CTAD 2026 by